Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 4Leukemia 4Anemia, Refractory, with Excess of Blasts 3Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Diseases 2Blast Crisis 2Preleukemia 1Neutropenia 1Myeloproliferative Disorders 1Anemia, Refractory 1

Interventions

fludarabine 3Melphalan 3fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2venetoclax 1spartalizumab 1sabatolimab 1ruxolitinib 1lintuzumab 1Sertraline 1Sampling Studies 1Lenalidomide 1Decitabine 1CPI-0610 1Biopsy 1Azacitidine 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Preleukemia × lintuzumab × Myeloid × Clear all
NCT00502112 2011-10-12

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Seagen Inc.

Phase 1 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Preleukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡